Ronald Primas, MD | Support HB1735

Dear Chair and Members of the House Health, Human Services, and Elderly Affairs Committee, My name is Dr. Ronald A. Primas, and I am a board-certified internist and preventive medicine physician with a clinical and professional focus on longevity, metabolic health, and innovation in age-related and chronic disease care. I currently practice in the Northeast and work closely with emerging biotechnology, diagnostics, and translational medicine initiatives. I am writing in strong support of HB 1734 and HB 1735 and respectfully urge the Committee to recommend both bills favorably. These bills represent thoughtful, patient-centered policy that balances safety with innovation. By modernizing New Hampshire’s experimental treatment framework and expanding right-to-try access beyond terminal illness to include serious chronic and debilitating conditions, the state sends a clear signal that it welcomes responsible biomedical innovation and compassionate care. From a practical standpoint, legislation such as HB 1734 and HB 1735 meaningfully lowers barriers for early-stage biotech and clinical innovators who are currently concentrated in Boston and other major hubs. New Hampshire is well positioned to attract these companies by offering a regulatory environment that supports ethical experimentation, translational research, and rapid iteration—while maintaining appropriate oversight. As a physician working at the intersection of clinical medicine and innovation, I see firsthand how patients with chronic, progressive conditions often exhaust standard options long before their disease is considered “terminal.” Expanding access in a structured and lawful manner is not only humane—it accelerates learning, data generation, and therapeutic advancement. Importantly, these bills also enhance New Hampshire’s competitiveness. If enacted, they would make the state more attractive for biotech startups, clinical research operations, and affiliated professional services seeking proximity to Boston’s talent pool without Boston’s regulatory and cost constraints. I would personally be interested in exploring the possibility of locating portions of clinical, advisory, or innovation-related work in New Hampshire should this legislative framework move forward. In summary, HB 1734 and HB 1735 promote innovation, patient autonomy, and economic development simultaneously. They reflect forward-looking leadership and would position New Hampshire as a national model for responsible biotech policy. Thank you for your time, consideration, and service. Respectfully submitted, Ronald A. Primas, MD, FACP, FACPM Board-Certified Internal Medicine & Preventive Medicine